mos Health (US:COSM)2026-04-15 20:34Sales and Market Performance - The Company recognized over 98% of its net sales in markets outside the United States in 2025, with initial sales in the U.S. through the Sky Premium Life nutraceutical brand[113]. - Changes in consumer behavior have shifted towards basic necessities and digital channels, impacting the Company's sales performance[111]. Economic Factors - The annual inflation rate in the European Union was approximately 2.3% in December 2025, reflecting a moderation compared to previous years[121]. - Inflationary pressures have led to higher costs for raw materials and increased overall operating costs, despite moderation in inflation during 2024 and 2025[122]. - The significant increase in global benchmark interest rates has adversely affected the Company, as most loan facilities carry floating interest rates, resulting in higher financing costs[123]. Regulatory and Legal Risks - The U.S. Inflation Reduction Act of 2022 may impact the Company by reducing out-of-pocket spending caps for Medicare beneficiaries and imposing new financial liabilities on certain drugs[124]. - Regulatory and litigation risks may restrict the Company's ability to sell products in certain markets or require changes to its business model[109]. Operational Challenges - The Company has been expanding its range of products and acquiring advanced technology for drug storage systems to ensure quality and accuracy in distribution[112]. - Cybersecurity risks pose a threat to the integrity of data, which could lead to significant legal and financial exposure for the Company[120]. - Geopolitical issues and conflicts, such as the war in Ukraine, could adversely affect the Company's operations and financial condition[114].